ABUS - Arbutus Biopharma Corp logo

ABUS

Arbutus Biopharma Corp

Arbutus Biopharma develops therapies for infectious diseases, focusing on chronic Hepatitis B. Its pipeline includes Imdusiran, an RNAi therapy in trials, and AB-101, an oral PD-L1 inhibitor aimed at boosting HBV-specific immune responses.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$1,279today

Score Overview

1 Year
Score
Net Growth6x
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth12x
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.5
Net Growth300.73%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth16x
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth139.85%
Net Trend70%
Net Income Consistency
Rev Growth121x
Rev Trend70%
Revenue Consistency
All Time
Score
Net Growth350.41%
Net Trend64%
Net Income Consistency
Rev Growth7x
Rev Trend64%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Arbutus Biopharma Corp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 5 years of fundamentals. ABUS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 4.86โ€”
1 Year2025-09-26
$ 4.4110.20%
5 Years2021-09-28
$ 4.3212.50%
10 Years2016-09-28
$ 3.8027.89%
All Time2015-08-03
$ 10.50-53.71%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 181M$ 153M$ 92M
2025$ 14M-$ 33M$ 91M
2024$ 6M-$ 69M$ 122M
2023$ 18M-$ 72M$ 126M
2022$ 39M-$ 69M$ 146M
2021$ 10M-$ 76M$ 155M
2020$ 6M-$ 63M$ 123M
2019$ 6M-$ 153M$ 90M
2018$ 5M-$ 57M$ 124M
2017$ 10M-$ 84M$ 126M
2016$ 1M-$ 384M$ 130M
IPO2015$ 24M-$ 61M$ 181M
ABUS - Arbutus Biopharma Corp logo

Arbutus Biopharma Corp fundamental performance

Between 2020 and 2025, revenue grew from $ 6M to $ 14M and net income went from -$ 63M to -$ 33M. Revenue increased in 3 of those 5 years; net income in 4.

Between 2015 and 2025, revenue declined from $ 24M to $ 14M and net income went from -$ 61M to -$ 33M. Revenue increased in 7 of those 10 years; net income in 7.

Arbutus Biopharma Corp currently holds a 5-year HDB Score of 7.5 out of 10. How the HDB Score is calculated.

Membership

Explore ABUS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies